Clinical Trial Update: Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating camrelizumab in combination with apatinib and albumin paclitaxel for advanced lung adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Albumin Paclitaxel (nab-paclitaxel)
• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Adenocarcinoma of the Lung | Phase 2 | Status: UNKNOWN